Keyphrases
Adjuvant Chemotherapy
11%
Adverse Events
7%
Antibody-drug Conjugate
8%
Binimetinib
7%
BRAF V600E mutant
6%
Brain Metastases
7%
Brentuximab Vedotin
7%
C-Met
6%
Carboplatin-paclitaxel
6%
Chemotherapy
26%
Clinical Trials
9%
Confidence Interval
13%
Diffuse Large B-cell Lymphoma (DLBCL)
8%
Docetaxel
7%
Dose Escalation
6%
Encorafenib
7%
End Results Database
8%
Erlotinib
8%
Hazard Ratio
7%
Histology
7%
Immune Checkpoint Inhibitors
7%
Improved Survival
6%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
31%
Lung Cancer
32%
Lymphoma
6%
Maximum Tolerated Dose
7%
Median Overall Survival
9%
Median Progression-free Survival
6%
Metastatic Non-small Cell Lung Cancer
11%
Nab-paclitaxel
11%
National Cancer Database
11%
NCCN Guidelines
10%
Nivolumab
10%
Non-small Cell Lung Cancer (NSCLC)
100%
Non-squamous Non-small Cell Lung Cancer
6%
Overall Response Rate
6%
Overall Survival
17%
Patient Selection
6%
Phase 1 Study
7%
Phase II Study
9%
Phase II Trial
7%
Platinum-based Chemotherapy
7%
Previously Treated
13%
Progression-free Survival
6%
Rovalpituzumab Tesirine
7%
Small Cell Lung Cancer
22%
Solid Tumors
6%
Surveillance Epidemiology
15%
Targeted Therapy
17%
Tumor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
16%
Antibody Drug Conjugate
5%
Binimetinib
7%
Biological Marker
10%
Brain Metastasis
7%
Carboplatin
12%
Chemoradiation Therapy
6%
Chemotherapy
30%
Clinical Trial
11%
Diffuse Large B Cell Lymphoma
5%
Disease
21%
Docetaxel
7%
Durvalumab
5%
Encorafenib
7%
Epidermal Growth Factor Receptor
5%
Erlotinib
6%
Etoposide
5%
Immune Checkpoint Inhibitor
6%
Immunotherapy
11%
Lung Cancer
40%
Malignant Neoplasm
24%
Maximum Tolerated Dose
6%
Monotherapy
5%
Neoplasm
23%
Neuroendocrine Tumor
5%
Nivolumab
9%
Non Small Cell Lung Cancer
80%
Overall Survival
22%
Paclitaxel
19%
Pembrolizumab
5%
Progression Free Survival
13%
Rovalpituzumab Tesirine
7%
Small Cell Lung Cancer
25%
Solid Malignant Neoplasm
12%
Squamous Cell Carcinoma
5%
Telisotuzumab Vedotin
7%
Medicine and Dentistry
Adjuvant Chemotherapy
9%
Adverse Event
7%
Biological Marker
9%
Brain Metastasis
7%
Carboplatin
6%
Chemoradiotherapy
7%
Chemotherapy
23%
Circulating Tumor DNA
5%
Clinical Oncology
5%
Clinical Stage
5%
Diffuse Large B-Cell Lymphoma
6%
Disease
21%
Etoposide
5%
Hazard Ratio
5%
Immunotherapy
12%
Lung
5%
Lung Cancer
40%
Malignant Neoplasm
21%
Neoplasm
19%
Nivolumab
7%
Non Small Cell Lung Cancer
78%
Non-Small Cell Lung Cancer
7%
Odds Ratio
5%
Overall Survival
26%
Paclitaxel
9%
Progression Free Survival
6%
Radiation Therapy
10%
Rovalpituzumab Tesirine
7%
Small Cell Lung Cancer
21%
Surgery
18%
Surveillance, Epidemiology, and End Results
14%
Targeted Therapy
14%